| Literature DB >> 33312033 |
Ali Bulbul1, Dilek Kabakci Kaya1, Gulperi Yagar Keskin1, Gulsen Kose2, Lida Bulbul3, Gizem Kara Elitok1, Ebru Ayyildiz1, Evrim Kiray Bas1, Sinan Uslu1.
Abstract
OBJECTIVES: This study aimed to evaluate the neuromotor development of premature babies and to determine the risk factors affecting neuromotor development in the middle time (3 years).Entities:
Keywords: Premature; morbidity; neuromotor development
Year: 2020 PMID: 33312033 PMCID: PMC7729721 DOI: 10.14744/SEMB.2020.06881
Source DB: PubMed Journal: Sisli Etfal Hastan Tip Bul ISSN: 1302-7123
Figure 1Flow diagram of the study.
The prenatal, natal and postnatal features of the cases and their demographic characteristics during hospitalization in the neonatal period
| Mean±SD | Lower and upper limits | |
|---|---|---|
| Birth weight, g | 1542.1±518.5 | 625-2950 |
| n | % | |
| 25-26 | 11 | 11.5 |
| 27-28 | 5 | 5.2 |
| 29-30 | 19 | 19.8 |
| 31-32 | 42 | 43.8 |
| 33-34 | 19 | 19.8 |
| Antenatal steroid use | 51 | 53.1 |
| Apgar score, (1. min <7) | 54 | 56.3 |
| Apgar score (5. min <7) | 12 | 12.5 |
| Mode of delivery, cesarean | 86 | 89.4 |
| Diagnoses at hospitalisation | ||
| Respiratory Distress Syndrome | 27 | 28.1 |
| Bronchopulmonary Dysplasia | 20 | 20.8 |
| Mild | 17 | 17.7 |
| Moderate | 3 | 3.1 |
| Sepsis | 20 | 20.8 |
| Necrotizing Enterocholitis | 25 | 26 |
| Stage 1 | 20 | 20.8 |
| Stage 2 | 5 | 5.2 |
| Intraventricular bleeding | 24 | 25 |
| Stage 1 | 16 | 16.6 |
| Stage 2 | 4 | 4.2 |
| Stage 3 | 4 | 4.2 |
| Treatments administered at admission | ||
| Oxygen support | 88 | 91.7 |
| Mechanical ventilation support | 42 | 43.8 |
| Continuous positive airway pressure | 68 | 70.8 |
| Surfactant | 27 | 28.1 |
| Caffeine | 45 | 46.9 |
| Antibiotics | 88 | 91.7 |
| Steroid therapy with the indication of bronchopulmonary dysplasia | ||
| Once | 15 | 15.6 |
| Twice | 5 | 5.2 |
| Length of hospital stay, days | 40±28.9 | 5-166 |
| Oxygen requirement time, days | 20.1±27.3 | 1-166 |
| Duration of mechanical ventilation, days | 10.5±17.4 | 1-83 |
| Duration of CPAP application, days | 5.6±6.3 | 1-33 |
| Duration of antibiotherapy, days | 14.3±11.8 | 3-74 |
SD: Standard deviation.
Midterm (for a period of three years) results of neurological examination, and DDST-II tests of the cases
| n | % | |
|---|---|---|
| Neurological examination results | ||
| Normal | 85 | 88.5 |
| Abnormal | 11 | 11.5 |
| DDST-II | ||
| Normal | 81 | 84.4 |
| Abnormal | 15 | 15.6 |
| Distribution of DDST-II test results | ||
| Abnormal Personal–Social Development | 4 | 4.2 |
| Abnormal fine motor development | 6 | 6.3 |
| Abnormal development of language | 5 | 5.2 |
| Abnormal gross motor development | 9 | 9.4 |
DGTT-II: Denver II Developmental Screening Test.
Evaluation of neurological examination results, and risk factors of the cases
| Neurological examination results | p | ||
|---|---|---|---|
| Normal n=85 | Abnormal n=11 | ||
| Mean±SD | |||
| Birth weight, g | 1598.8±503.9 | 1103.8±427.8 | <0.001 |
| Gestational weeks | 30.9±2.3 | 28.6±2.6 | 0.003 |
| n (%) | n (%) | ||
| Gestational weeks | 0.031 | ||
| 25-26 | 7 (7.3) | 4 (4.2) | |
| 27-28 | 4 (4.2) | 1 (1) | |
| 29-30 | 16 (16.7) | 3 (3.1) | |
| 31-32 | 39 (40.6) | 3 (3.1) | |
| 33-34 | 19 (19.8) | 0 (0) | |
| Apgar score (1st min <7) | 44 (45.8) | 10 (10.4) | 0.021 |
| Apgar score (5th min <7) | 7 (7.3) | 5 (5.2) | 0.004 |
| Bronchopulmonary dysplasia | 14 (14.6) | 6 (6.3) | 0.009 |
| Sepsis | 14 (14.6) | 6 (6.3) | 0.009 |
| Intraventricular bleeding | 18 (18.8) | 6 (6.3) | 0.026 |
| Requirement for mechanical ventilation | 32 (33.3) | 10 (10.4) | 0.001 |
| Surfactant treatment | 21 (21.9) | 6 (6.3) | 0.069 |
| Duration of oxygen therapy | 15.5±19.4 (7) | 52.8±47.9 (40) | 0.001 |
| Duration of CPAP application | 5.3±6.4 (3) | 7.7±5.3 (6) | 0.024 |
CPAP: Continuous Positive Airway Pressure.
Evaluation of the factors effective on DDST-II results
| DDST-II test results | p | ||
|---|---|---|---|
| Normal n=81 | Abnormal n=15 | ||
| Mean±SD | |||
| Birth weight g | 1616.4±497 | 114.9±456.8 | 0.001 |
| Gestational weeks | 31±2.2 | 28.5±2.8 | 0.001 |
| n (%) | |||
| Gestational weeks | 0.002 | ||
| 25-26 | 5 (5.2) | 6 (6.3) | |
| 27-28 | 4 (4.2) | 1 (1) | |
| 29-30 | 15 (15.6) | 4 (4.2) | |
| 31-32 | 39 (40.6) | 3 (3.1) | |
| 33-34 | 18 (18.8) | 1 (1) | |
| Apgar score (5th min <7) | 6 (6.3) | 6 (6.3) | 0.003 |
| Respiratory distress syndrome | 19 (19.8) | 8 (8.3) | 0.028 |
| Bronchopulmonary displasia | 11 (11.5) | 9 (9.4) | 0.001 |
| Sepsis | 13 (13.5) | 7 (7.3) | 0.014 |
| Requirement for mechanical ventilation | 30 (31.3) | 12 (12.5) | 0.005 |
| Surfactant treatment | 19 (19.8) | 8 (8.3) | 0.028 |
DDST-II: Denver II Developmental Screening Test; SD: Standard deviation.